A novel isoquinoline derivative anticancer agent and its targeted delivery to tumor cells using transferrin-conjugated liposomes

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Yang, Xuewei ^a   Yang, Shuang ^a   Chai, Hongyu ^a   Yang, Zhaogang ^b   Lee, Robert J ^a,b   Liao, Weiwei ^a   Teng, Lesheng ^a  

^a JILIN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; LIPOSOME; TRANSFERRIN; ACRYLIC ACID DERIVATIVE; DRUG CARRIER; LACTONE; QUINOLINE DERIVATIVE; TRANSFERRIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; INTERNALIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; TUMOR CELL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENDOCYTOSIS; HEP-G2 CELL LINE; METABOLISM; TUMOR CELL LINE;

ACRYLATES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCYTOSIS; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; ISOQUINOLINES; LACTONES; LIPOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; QUINOLINES; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 84943328017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136649     Document Type: Article

References (30)

1. Bentley KW. beta-Phenylethylamines and the isoquinoline alkaloids. Nat Prod Rep. 2006; 23(3):444-63. Epub 2006/06/03. doi: 10.1039/b509523a PMID: 16741588.
2. Kitson RR, Millemaggi A, Taylor RJ. The renaissance of alpha-methylene-gamma-butyrolactones: new synthetic approaches. Angew Chem Int Ed Engl. 2009; 48(50):9426-51. Epub 2009/11/26. doi: 10. 1002/anie.200903108 PMID: 19938025.
3. Janecka A, Wyrebska A, Gach K, Fichna J, Janecki T. Natural and synthetic alpha-methylenelactones and alpha-methylenelactams with anticancer potential. Drug Discov Today. 2012; 17(11-12):561-72. Epub 2012/02/09. doi: S1359-6446(12)00015-3 [pii]doi: 10.1016/j.drudis.2012.01.013 PMID: 22309965.
4. Qin TY, Liao WW, Zhang YJ, Zhang SXA. Asymmetric organocatalytic allylic alkylation of Reissert compounds: a facile access to chiral 1,1-disubstituted 1,2-dihydroisoquinolines. Org Biomol Chem. 2013; 11(6):984-90. doi: 10.1039/c2ob27269e PMID: WOS:000313664100014.
5. Yan Y, En D, Zhuang Z, Guo Y, Liao WW. Synthesis of densely functionalized alpha-methylene gamma-butyrolactones via an organocatalytic one-pot allylic-alkylation-cyclization reaction. Tetrahedron Lett. 2014; 55(2):479-82. doi: 10.1016/j.tetlet.2013.11.067 PMID: WOS:000329946900046.
6. Moodley S, Koorbanally NA, Moodley T, Ramjugernath D, Pillay M. The 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) assay is a rapid, cheap, screening test for the in vitro anti-tuberculous activity of chalcones. J Microbiol Methods. 2014; 103:72-8. doi: 10.1016/j.mimet.2014.06.014 PMID: WOS:000340986800013.
7. Farooq S, Shakeel UR, Hussain A, Hamid A, Qurishi MA, Koul S. Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents. Eur J Med Chem. 2014; 84:545-54. doi: 10.1016/j.ejmech.2014.07.069 PMID: WOS:000341464500050.
8. Martin A, Morcillo N, Lemus D, Montoro E, Telles MAD, Simboli N, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2005; 9(8):901-6. PMID: WOS:000231073200014.
9. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, et al. Liposomes bearing polyethyleneglycol- coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res. 2001; 18(7):1042-8. doi: 10.1023/a:1010960900254 PMID: WOS:000170027500022.
10. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs. 1998; 56(5):747-56. doi: 10.2165/00003495-199856050-00001 PMID: MEDLINE:9829150.
11. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm. 2004; 281(1-2):25-33. doi: 10.1016/j.ijpharm.2004.05.025 PMID: WOS:000223499300003.
12. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006; 121(2):159-76. doi: 10.1016/j.clim.2006.06. 006 PMID: WOS:000241638900004.
13. Zhou CG, Yang ZG, Teng LS. Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives. Curr Pharm Biotechnol. 2014; 15(9):829-38. PMID: WOS:000345277100008.
14. Sakaguchi N, Kojima C, Harada A, Koiwai K, Emi N, Kono K. Effect of transferrin as a ligand of pH-sensitive fusogenic liposome-lipoplex hybrid complexes. Bioconjugate Chem. 2008; 19(8):1588-95. doi: 10.1021/bc800126s PMID: WOS:000258600600012.
15. Fonseca C, Moreira JN, Ciudad CJ, Pedroso de Lima MC, Simoes S. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm. 2005; 59(2):359-66. Epub 2005/01/22. doi: S0939-6411(04)00256-5 [pii]doi: 10.1016/j.ejpb.2004.08.012 PMID: 15661509.
16. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014; 32(1):32-45. doi: 10.1016/j.tibtech. 2013.09.007 PMID: WOS:000329771900005.
17. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002; 22(3):225-50. Epub 2002/04/05. doi: 10.1002/med.10008 [pii]. PMID: 11933019.
18. Wang XM, Huang XM, Yang ZG, Gallego-Perez D, Ma JY, Zhao X, et al. Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells. Curr Pharm Biotechnol. 2014; 15(9):839-46. PMID: WOS:000345277100009.
19. Yang ZG, Yu B, Zhu J, Huang XM, Xie J, Xu SL, et al. A microfluidic method to synthesize transferrinlipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale. 2014; 6(16):9742-51. doi: 10.1039/c4nr01510j PMID: WOS:000340217900050.
20. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C. In vitro assessment of transferrin- conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci. 2006; 29(5):367-74. doi: 10.1016/j.ejps.2006.07.004 PMID: WOS:000242693900006.
21. Xu SL, Liu Y, Tai HC, Zhu J, Ding H, Lee RJ. Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation (vol 404, pg 205, 2011). Int J Pharm. 2011; 414(1-2):332-. doi: 10.1016/j.ijpharm. 2011.05.050 PMID: WOS:000292795500040.
22. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007; 329(1-2):94-102. doi: 10.1016/j.ijpharm.2006.08.039 PMID: WOS:000243773700012.
23. Hossen MN, Kajimoto K, Akita H, Hyodo M, Ishitsuka T, Harashima H. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. J Control Release. 2010; 147 (2):261-8. doi: 10.1016/j.jconrel.2010.07.100 PMID: WOS:000283566600016.
24. Chiu SJ, Liu SJ, Perrotti D, Marcucci G, Lee RJ. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release. 2006; 112 (2):199-207. doi: 10.1016/j.jconrel.2006.02.011 PMID: WOS:000237908100006.
25. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed. 2010; 5:101-8. PMID: WOS:000283715300009.
26. Ahamad MS, Siddiqui S, Jafri A, Ahmad S, Afzal M, Arshad M. Induction of Apoptosis and Antiproliferative Activity of Naringenin in Human Epidermoid Carcinoma Cell through ROS Generation and Cell Cycle Arrest. Plos One. 2014; 9(10):8. doi: 10.1371/journal.pone.0110003 PMID: WOS:000343210800051.
27. Prathapan A, Vineetha VP, Raghu KG. Protective Effect of Boerhaavia diffusa L. against Mitochondrial Dysfunction in Angiotensin II Induced Hypertrophy in H9c2 Cardiomyoblast Cells. Plos One. 2014; 9 (4):13. doi: 10.1371/journal.pone.0096220 PMID: WOS:000338917300033.
28. Xie J, Teng LS, Yang ZG, Zhou CG, Liu Y, Yung BC, et al. A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery. Biomed Res Int. 2013:7. doi: 10.1155/2013/710502 PMID: WOS:000320267800001.
29. Li X, Ding L, Xu Y, Wang Y, Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm. 2009; 373(1-2):116-23. Epub 2009/05/12. doi: S0378-5173(09)00058-1 [pii]doi: 10.1016/j.ijpharm.2009.01.023 PMID: 19429296.
30. Yang ZG, Sun W, Hu KL. Adenosine A(1) receptors selectively target protein kinase C isoforms to the caveolin-rich plasma membrane in cardiac myocytes. Biochim Biophys Acta-Mol Cell Res. 2009; 1793 (12):1868-75. doi: 10.1016/j.bbamcr.2009.10.007 PMID: WOS:000273112400009.